EGFR and non-small cell lung carcinoma: The result showed that the migration, invasion, adhesion, tumor perimeter, and mesenchymal phenotype were increased in the H292 KRAS mutated cells, and everolimus restored sensibility and improved cytotoxicity of EGFR inhibitors in the KRAS mutant NSCLC cell lines (da Silva-Oliveira et al., 2022).